April 2025 in “Advances in Traditional Medicine” Rosemary essential oil spray can effectively increase hair density in alopecia treatment.
March 2025 in “Pediatric Rheumatology” Cyclophosphamide is preferred for severe cases in pediatric rheumatology and nephrology despite its side effects.
November 2024 in “Journal of Clinical Medicine” The treatment improved hair thickness, shine, and reduced hair loss effectively.
36 citations
,
May 2025 in “Antioxidants” Lipid peroxidation worsens skin diseases but may help treat cancer.
7 citations
,
January 1990 November 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is generally safe for adolescents with alopecia areata over 5 years.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib 50 mg effectively promotes and sustains hair regrowth in alopecia areata patients.
2 citations
,
June 2024 in “Dermatology” Ritlecitinib improves hair regrowth satisfaction in alopecia areata patients.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is effective long-term for treating alopecia areata in teens.
March 2025 in “SKIN The Journal of Cutaneous Medicine” 3 citations
,
July 2025 in “Clinical and Experimental Dermatology” Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.
May 2025 in “Russian Journal of Allergy” Combining antihistamines with topical treatment improves hair regrowth in alopecia areata.
April 2019 in “Biometrics” The new clinical trial design is promising but needs real-world trials to test its effectiveness and possible enhancements.
3 citations
,
March 2017 in “Regulatory toxicology and pharmacology” Aleglitazar and its major metabolite are safe enough to proceed to Phase 3 clinical trials.
January 1975 in “NJEA Review” The drug showed promise in treating renal cell carcinoma with manageable side effects.
August 2024 in “British Journal of Dermatology” Rezpegaldesleukin shows promise for treating severe alopecia areata.
4 citations
,
September 2024 in “BMC Cancer” 5 citations
,
March 2020 in “Thoracic Cancer” CT-707 is effective and safe for treating certain Chinese lung cancer patients.
September 2002 in “Oncology Times” Promising cancer treatments were found, but the manufacturer closed.
93 citations
,
May 2010 in “European Journal of Cancer” BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.
September 2023 in “Journal of the American Academy of Dermatology” October 2025 in “Dermatology and Therapy” 1 citations
,
August 2021 in “Journal of Investigative Dermatology” ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.
March 2005 in “Journal of the American Academy of Dermatology” Bexarotene 1% topical gel helped some patients with alopecia areata regrow hair.
January 2025 in “Recent Patents on Anti-Cancer Drug Discovery” The treatment showed high response rates and was well-tolerated, potentially extending patient survival.
12 citations
,
May 2010 in “Journal of Clinical Oncology” MK-5108 is safe and shows potential against tumors, especially alone.
148 citations
,
March 2022 in “The New England Journal of Medicine” Baricitinib was effective in treating alopecia areata in two major trials.
1 citations
,
August 2021 in “Journal of The American Academy of Dermatology” Baricitinib helped improve hair, eyebrow, and eyelash growth in alopecia areata patients.
78 citations
,
March 2004 in “Annals of Oncology” The treatment combining docetaxel, cisplatin, and 5-FU is feasible and effective for advanced head and neck cancer.
Hair regrowth improved, but quality of life did not.